← All trials
NCT05749926
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 16, 2023
- Primary completion
- Jul 12, 2023
- Completion date
- Jul 12, 2024
- First posted
- Mar 1, 2023
- Last posted
- Jun 29, 2023
- Enrollment
- 248
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- COVIREIVACCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.